Shots:

• The approval is based on data from the P-II LOTIS-2 trial involves assessing Zynlonta in adults with r/r DLBCL following two or more prior lines of systemic therapy
• Results: ORR (48.3%); CRR (24.1)- PR (24.1%)- and mDoR in 70 responders (10.3mos.) with a median time to response of 1.3 mos. The therapy will be commercially available in the US imminently
• Zynlonta is the 1st CD19-targeted ADC approved as a monothx. for adult patients with r/r DLBCL. The company has launched the patient support program to provide financial assistance- education- and other resources for patients who are prescribed the therapy

­ Ref: Businesswire | Image: ADC Therapeutics